Literature DB >> 21846717

Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes.

Xuan Ge1, Cheng Chen, Xiaoyan Hui, Yu Wang, Karen S L Lam, Aimin Xu.   

Abstract

Fibroblast growth factor 21 (FGF21) is a liver-secreted endocrine factor with multiple beneficial effects on obesity-related disorders. It enhances glucose uptake by inducing the expression of glucose transporter-1 (GLUT1) in adipocytes. Here we investigated the signaling pathways that mediate FGF21-induced GLUT1 expression and glucose uptake in vitro and in animals. Quantitative real-time PCR and a luciferase reporter assay showed that FGF21 induced GLUT1 expression through transcriptional activation. The truncation of the GLUT1 promoter from -3145 to -3105 bp, which contains two highly conserved serum response element (SRE) and E-Twenty Six (ETS) binding motif, dramatically decreased FGF21-induced promoter activity of the GLUT1 gene. A chromatin immunoprecipitation assay demonstrated that the transcription factors serum response factor (SRF) and Ets-like protein-1 (Elk-1) were recruited to the GLUT1 promoter upon FGF21 stimulation. The siRNA-mediated knockdown of either SRF or Elk-1 resulted in a marked attenuation in FGF21-induced GLUT1 expression and glucose uptake in adipocytes. In C57 lean mice, a single intravenous injection of FGF21 induced phosphorylation of Elk-1 at Ser(383) and SRF at Ser(103) and also led to the recruitment of Elk-1 and SRF to the GLUT1 promoter in epididymal fats. By contrast, such effects of in vivo FGF21 administration were blunted in high fat diet-induced obese mice. In conclusion, FGF21 induces GLUT1 expression and glucose uptake through sequential activation of ERK1/2 and SRF/Elk-1, which in turn triggers the transcriptional activation of GLUT1 in adipocytes. The impairment in this signaling pathway may contribute to FGF21 resistance in obese mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846717      PMCID: PMC3186365          DOI: 10.1074/jbc.M111.248591

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

2.  Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

Authors:  Wolf Wente; Alexander M Efanov; Martin Brenner; Alexei Kharitonenkov; Anja Köster; George E Sandusky; Sabine Sewing; Iris Treinies; Heike Zitzer; Jesper Gromada
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

3.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Authors:  Alexei Kharitonenkov; Victor J Wroblewski; Anja Koester; Yun-Fei Chen; Cathleen K Clutinger; Xenia T Tigno; Barbara C Hansen; Armen B Shanafelt; Garret J Etgen
Journal:  Endocrinology       Date:  2006-10-26       Impact factor: 4.736

4.  FGF-21 as a novel metabolic regulator.

Authors:  Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

5.  Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.

Authors:  Regina Goetz; Andrew Beenken; Omar A Ibrahimi; Juliya Kalinina; Shaun K Olsen; Anna V Eliseenkova; ChongFeng Xu; Thomas A Neubert; Fuming Zhang; Robert J Linhardt; Xijie Yu; Kenneth E White; Takeshi Inagaki; Steven A Kliewer; Masaya Yamamoto; Hiroshi Kurosu; Yasushi Ogawa; Makoto Kuro-o; Beate Lanske; Mohammed S Razzaque; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

6.  Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes.

Authors:  Hong Wang; Li Qiang; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

7.  BetaKlotho is required for metabolic activity of fibroblast growth factor 21.

Authors:  Yasushi Ogawa; Hiroshi Kurosu; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Makoto Kuro-o
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

Review 8.  Mini-review: endocrine actions of fibroblast growth factor 19.

Authors:  Stacey Jones
Journal:  Mol Pharm       Date:  2008-01-08       Impact factor: 4.939

9.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.

Authors:  Takeshi Inagaki; Paul Dutchak; Guixiang Zhao; Xunshan Ding; Laurent Gautron; Vinay Parameswara; Yong Li; Regina Goetz; Moosa Mohammadi; Victoria Esser; Joel K Elmquist; Robert D Gerard; Shawn C Burgess; Robert E Hammer; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

10.  betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c.

Authors:  Masashi Suzuki; Yuriko Uehara; Kaori Motomura-Matsuzaka; Junko Oki; Yoshinori Koyama; Miho Kimura; Masahiro Asada; Akiko Komi-Kuramochi; Syuichi Oka; Toru Imamura
Journal:  Mol Endocrinol       Date:  2008-01-10
View more
  61 in total

1.  FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway.

Authors:  Yumei Li; Jiangnan Huang; Zhiyuan Jiang; Yang Jiao; Hui Wang
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  The host response to poly(lactide-co-glycolide) scaffolds protects mice from diet induced obesity and glucose intolerance.

Authors:  Michael A Hendley; Kendall P Murphy; Christopher Isely; Heather L Struckman; Prakasam Annamalai; R Michael Gower
Journal:  Biomaterials       Date:  2019-06-19       Impact factor: 12.479

3.  Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway.

Authors:  Chi Zhang; Zhifeng Huang; Junlian Gu; Xiaoqing Yan; Xuemian Lu; Shanshan Zhou; Shudong Wang; Minglong Shao; Fangfang Zhang; Peng Cheng; Wenke Feng; Yi Tan; Xiaokun Li
Journal:  Diabetologia       Date:  2015-06-04       Impact factor: 10.122

Review 4.  A review of fibroblast growth factor 21 in diabetic cardiomyopathy.

Authors:  Xiang Zhang; Luo Yang; Xiongfeng Xu; Fengjuan Tang; Peng Yi; Bo Qiu; Yarong Hao
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

5.  Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice.

Authors:  Yu Li; Kimberly Wong; Kenneth Walsh; Bin Gao; Mengwei Zang
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

Review 6.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

7.  Brown adipose tissue regulates glucose homeostasis and insulin sensitivity.

Authors:  Kristin I Stanford; Roeland J W Middelbeek; Kristy L Townsend; Ding An; Eva B Nygaard; Kristen M Hitchcox; Kathleen R Markan; Kazuhiro Nakano; Michael F Hirshman; Yu-Hua Tseng; Laurie J Goodyear
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 8.  Adipose tissue, hormones, and treatment of type 1 diabetes.

Authors:  Subhadra C Gunawardana
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 9.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

Review 10.  MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity.

Authors:  T Fu; J K Kemper
Journal:  Vitam Horm       Date:  2016-03-21       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.